114 results
Page 2 of 6
8-K
EX-99.1
6zo5 j81wszh
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.2
48un2lcuf8 4p
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
4n9fj 3e5k8e
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
za2o33xtv64 duzl7
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
8-K
EX-99.1
nibp2w0iru yrai1pyon
7 Nov 23
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
EX-1.1
yauxehqpt1 xfvw8
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
424B5
n18jk lm9lkzok
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
buqlyvz2ewxx90ajru
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
a045huwu vkavo
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.2
qse6vrb8fq662 ll305m
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
mnzb7
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
x9vts46ast04hahva9qd
8 Aug 23
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:01am
8-K
EX-99.1
aqnhecxha3mq7n
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
nd61c4 zn8
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am